Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Candel Therapeutics Inc (CADL)

Candel Therapeutics Inc (CADL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 354,263
  • Shares Outstanding, K 47,235
  • Annual Sales, $ 0 K
  • Annual Income, $ -55,180 K
  • EBIT $ -33 M
  • EBITDA $ -32 M
  • 60-Month Beta -1.29
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.82

Options Overview Details

View History
  • Implied Volatility 114.96% ( +0.57%)
  • Historical Volatility 121.27%
  • IV Percentile 31%
  • IV Rank 24.41%
  • IV High 452.22% on 12/10/24
  • IV Low 6.03% on 04/15/24
  • Put/Call Vol Ratio 0.43
  • Today's Volume 4,737
  • Volume Avg (30-Day) 1,236
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 23,132
  • Open Int (30-Day) 26,788

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.24
  • Number of Estimates 1
  • High Estimate -0.24
  • Low Estimate -0.24
  • Prior Year -0.28
  • Growth Rate Est. (year over year) +14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.75 +2.96%
on 03/27/25
9.13 -23.88%
on 03/03/25
-1.65 (-19.19%)
since 02/27/25
3-Month
6.31 +10.14%
on 01/28/25
13.68 -49.20%
on 02/20/25
-1.92 (-21.65%)
since 12/27/24
52-Week
1.53 +354.25%
on 03/28/24
14.60 -52.40%
on 12/11/24
+5.41 (+351.30%)
since 03/27/24

Most Recent Stories

More News
Candel’s Final Survival Data From Lung Cancer Drug Trial Lifts Stock After-Hours, Fuels Retail Optimism

The study included 46 fully treated patients, with 37% of those with progressive disease still alive after two years.

CADL : 6.95 (-7.33%)
VTI : 278.99 (-0.42%)
HDG : 49.11 (-0.03%)
IWM : 204.61 (-0.48%)
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment

CADL : 6.95 (-7.33%)
Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409

CADL : 6.95 (-7.33%)
Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board

CADL : 6.95 (-7.33%)
Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

CADL : 6.95 (-7.33%)
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

CADL : 6.95 (-7.33%)
Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week

Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments.

SLDB : 4.37 (+2.58%)
SLRN : 2.64 (+3.94%)
ESLA : 0.9300 (-5.10%)
CADL : 6.95 (-7.33%)
ADTX : 6.16 (-10.00%)
Candel Therapeutics Stock Rallies On Canaccord’s Vote Of Confidence In Lead Cancer Drug: Retail Traders Rejoice

CAN-2409 could become a “best-in-class therapy” for borderline resectable pancreatic ductal adenocarcinoma, according to the analyst.

CADL : 6.95 (-7.33%)
VTI : 278.99 (-0.42%)
HDG : 49.11 (-0.03%)
IWM : 204.61 (-0.48%)
Candel Therapeutics Stock Headed For 20% Weekly Gains: Retail Over The Moon With BofA's 'Buy' Call

The analyst noted that CAN-2409's early data in prostate cancer suggests the potential for a meaningful breakthrough, given the lack of significant advancements in available treatments.

CADL : 6.95 (-7.33%)
VTI : 278.99 (-0.42%)
HDG : 49.11 (-0.03%)
IWM : 204.61 (-0.48%)
Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025

CADL : 6.95 (-7.33%)

Business Summary

Candel Therapeutics Inc. is a late clinical stage biopharmaceutical company. It involved in developing novel oncolytic viral immunotherapies. The company's product pipeline includes CAN-2409 and CAN-3110. Candel Therapeutics Inc. is based in NEEDHAM, Mass.

See More

Key Turning Points

3rd Resistance Point 8.47
2nd Resistance Point 8.08
1st Resistance Point 7.52
Last Price 6.95
1st Support Level 6.57
2nd Support Level 6.18
3rd Support Level 5.62

See More

52-Week High 14.60
Fibonacci 61.8% 9.61
Fibonacci 50% 8.07
Last Price 6.95
Fibonacci 38.2% 6.52
52-Week Low 1.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar